carecentrix

Provider Newsflash
October 2023

FDA Recall – Hospira, Inc.

Purpose of this communication:

- We are writing to inform you that the FDA has issued notice of voluntary recall by Hospira, Inc. a Pfizer company of their 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 ml vial (0.5 mEq/mL), Lot number GJ5007, 1% Lidocaine HCL Injection, USP 50 mg/5 mL vial (10 mg/mL), Lot number 42290DK, and 2% Lidocaine HCL Injection, USP 100 mg/5 mL (20 mg/mL) vial, Lot number GH6567 distributed nationwide between October 13, 2022 and October 26, 2022. This recall was initiated due to the potential for the presence of glass particulate matter in the vials.

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-42-sodium-bicarbonate-injection-usp-and-1-and-2?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.